The effects of equi-efficacious doses of the cholesterol-lowering drugs simvastatin (20 mg day-1) and pravastatin (40 mg day-1) on tests of cognitive function were investigated in a double-blind, placebo-controlled, 2-period (4 weeks per period), incomplete block, crossover study of 36 patients (24 per treatment) with hypercholesterolaemia. After 4 weeks neither of the active treatments differed significantly from placebo on any cognitive measure.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1365013PMC
http://dx.doi.org/10.1111/j.1365-2125.1995.tb04458.xDOI Listing

Publication Analysis

Top Keywords

cognitive function
8
effects treatment
4
treatment simvastatin
4
simvastatin pravastatin
4
pravastatin cognitive
4
function patients
4
patients hypercholesterolaemia
4
hypercholesterolaemia effects
4
effects equi-efficacious
4
equi-efficacious doses
4

Similar Publications

Pharmacological Aspects in the Management of Children and Adolescents with Prader-Willi Syndrome.

Paediatr Drugs

January 2025

Division of Endocrinology, Department of Pediatrics, University of Florida, PO Box 100296, Gainesville, FL, 32610, USA.

Prader-Willi syndrome is a rare neurodevelopmental disorder that impacts the musculoskeletal, endocrine, pulmonary, neurologic, ocular, and gastrointestinal systems. In addition, individuals with Prader-Willi syndrome have issues with cognitive development, characteristic behavioral problems, and perhaps most profoundly, appetite control. Currently, the only US Food and Drug Administration-approved therapy for Prader-Willi syndrome is growth hormone, which has been Food and Drug Administration approved for > 20 years for the treatment of growth failure in Prader-Willi syndrome.

View Article and Find Full Text PDF

Cognitive variation reflects amyloid, tau, and neurodegenerative biomarkers in Alzheimer's disease.

Geroscience

January 2025

Psychology, School of Social Sciences, Nanyang Technological University, 48 Nanyang Avenue S639818, Singapore, Singapore.

In Alzheimer's disease (AD), the accumulation of neuropathological markers such as amyloid-β plaques, neurofibrillary tangles, and cortical neurodegeneration occurs over many years before overt manifestation of cognitive impairment. There is thus a need for neuropsychological markers that are indicative of pathological changes in the early stages of the disease. Intra-individual cognitive variability (IICV), defined as the variation of an individual's performance across cognitive domains, is a promising neuropsychological marker measuring heterogeneous changes in cognition that may reflect these early pathological changes.

View Article and Find Full Text PDF

Highly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer's disease patients.

Ann Nucl Med

January 2025

Department of Radiological Sciences, School of Health Science, Fukushima Medical University, 10-6 Sakae, Fukushima City, Fukushima, 960-8516, Japan.

Objective: This study aims to accurately classify ATN profiles using highly specific amyloid and tau PET ligands and MRI in patients with cognitive impairment and suspected Alzheimer's disease (AD). It also aims to explore the relationship between quantified amyloid and tau deposition and cognitive function.

Methods: Twenty-seven patients (15 women and 12 men; age range: 64-81 years) were included in this study.

View Article and Find Full Text PDF

EEG involves recording electrical activity generated by the brain through electrodes placed on the scalp. Imagined speech classification has emerged as an essential area of research in brain-computer interfaces (BCIs). Despite significant advances, accurately classifying imagined speech signals remains challenging due to their complex and non-stationary nature.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!